title: AbobotulinumtoxinA (Dysport®) Improves Function According to Goal Attainment in Children With Dynamic Equinus Due to Cerebral Palsy.
abstract: This secondary analysis of a large (n = 241), randomized, double-blind study evaluated the efficacy of 2 doses of abobotulinumtoxinA + standard of care (SOC) versus placebo + SOC in enabling children with dynamic equinus due to cerebral palsy to achieve their functional goals using Goal Attainment Scaling. Most parents/caregivers selected goals targeting aspects of gait improvement as most relevant. Mean (95% confidence interval) Goal Attainment Scaling T scores at week 4 were higher for both abobotulinumtoxinA groups versus placebo (treatment difference vs placebo: 10 U/kg/leg: 5.32 [2.31, 8.32], P = .0006, and 15 U/kg/leg 4.65 [1.59, 7.71], P = .0031). Superiority of both abobotulinumtoxinA doses versus placebo was maintained at week 12. Best goal attainment T scores were higher in the abobotulinumtoxinA groups versus placebo for the common goals of improved walking pattern, decreased falling, decreased tripping, and improved endurance. These findings demonstrate that single injections of abobotulinumtoxinA (10 and 15 U/kg/leg) significantly improved the ability of pediatric cerebral palsy patients to achieve their functional goals.
authors.affiliation: 1 LSUHSC and Children's Hospital New Orleans, New Orleans, LA, USA.
authors.forename: Ann
authors.initials: A
authors.lastname: Tilton
authors.affiliation: 2 Shriner's Hospital for Children, Portland, OR, USA.
authors.forename: Barry
authors.initials: B
authors.lastname: Russman
authors.affiliation: 3 Istanbul University, Istanbul, Turkey.
authors.forename: Resa
authors.initials: R
authors.lastname: Aydin
authors.affiliation: 4 GATA Haydarpasa Training Hospital, Istanbul, Turkey.
authors.forename: Umit
authors.initials: U
authors.lastname: Dincer
authors.affiliation: 5 Unit of Neurology, Division of Pediatrics, Medical School, Pontificia Universidad Catolica de Chile, Santiago, Chile.
authors.forename: Raul G
authors.initials: RG
authors.lastname: Escobar
authors.affiliation: 6 Department of PMR, Ankara University, Faculty of Medicine, Ankara, Turkey.
authors.forename: Sehim
authors.initials: S
authors.lastname: Kutlay
authors.affiliation: 7 B and L-Specialist Medical Centre, Lodz, Poland.
authors.forename: Zbigniew
authors.initials: Z
authors.lastname: Lipczyk
authors.affiliation: 8 Club De Leones Cruz Del Sur Rehabilitation Center, Punta Arenas, Chile.
authors.forename: Juan Carlos
authors.initials: JC
authors.lastname: Velez
authors.affiliation: 9 Ipsen, Les Ulis, France.
authors.forename: Anne-Sophie
authors.initials: AS
authors.lastname: Grandoulier
authors.affiliation: 9 Ipsen, Les Ulis, France.
authors.forename: Anissa
authors.initials: A
authors.lastname: Tse
authors.affiliation: 9 Ipsen, Les Ulis, France.
authors.forename: Philippe
authors.initials: P
authors.lastname: Picaut
authors.affiliation: 10 University of Texas Southwestern Medical Center and Texas Scottish Rite Hospital for Children, Dallas, TX, USA.
authors.forename: Mauricio R
authors.initials: MR
authors.lastname: Delgado
mesh_terms: D000293:Adolescent; D019274:Botulinum Toxins, Type A / Q000494:pharmacology / Q000627:therapeutic use*; D002547:Cerebral Palsy / Q000150:complications / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D004311:Double-Blind Method; D004863:Equinus Deformity / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D005684:Gait / Q000187:drug effects*; D006040:Goals; D006801:Humans; D008297:Male; D009465:Neuromuscular Agents / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A; C542869:abobotulinumtoxinA
keywords: Dysport; abobotulinumtoxinA; cerebral palsy; equinus foot; goal attainment scaling